Close Menu

Patti Connolly, Paul Brenner

Feb 06, 2019

RenalytixAI has appointed Patti Connolly as its VP of clinical and scientific affairs. Connolly will lead the firm's recruitment efforts for the prospective clinical utility study for its KidneyIntelX assay, which the firm plans to begin in Q4 2019. Prior to RenalytixAI, Connolly served as clinical services director at Pearl Pathways.

RenalytixAI has also appointed and Paul Brenner to the firm's advisory board. Brenner currently serves as a computer science faculty member at the University of Notre Dame and associate director of Notre Dame's Center for Research Computing. Brenner also serves as a senior reserve advisor to the Air Force Cyber College Commandment.

More Like This

Feb 26, 2020

Thermo Fisher Scientific: Marc Casper, Jim Manzi, Thomas Lynch

Thermo Fisher Scientific's board of directors has elected Marc Casper its chairman, effective immediately. Casper, who is the company's president and CEO, succeeds Jim Manzi, who will continue to serve as a director on Thermo Fisher's board. Manzi has been a director at the company since May 2000 and was chairman of the board for 15 years. Also, Thomas Lynch has been elected as lead independent director, effective immediately. He has been a board member since May 2009. 

Feb 25, 2020

Centogene: Vaibhav Joshi

Centogene has named Vaibhav Joshi to the newly created role of chief data officer. He joins the company from Virgin Care, which provides health and social care services in the UK. He was chief data officer there. Before that Vaibhav was clinical informatics director at the Private Healthcare Information Network and clinical analytics lead at Ramsay Health Care UK. 

Feb 25, 2020

Guardant Health: Derek Bertocci

Guardant Health said that Derek Bertocci will be retiring from as the company's cheif financial officer during the second quarter of 2020. He will continue to serve in his current role until a successor is hired and plans to remain at Guardant and support the firm during this transition.

Feb 18, 2020

Proscia: Arun Ananthapadmanabhan

Proscia appointed Arun Ananthapadmanabhan its executive vice president of global growth to manage the company's international commercial operations. He joins the Philadelphia-based digital pathology firm from Philips, where he created and led the computational pathology business. Ananthapadmanabhan will be based in Amsterdam. 

Feb 14, 2020

Biocept: Cory Dunn

Biocept has promoted Cory Dunn to Senior VP of commercial operations, succeeding Edwin Hendrick, who resigned to pursue other endeavors. Dunn previously served as Biocept's VP of commercial operations, beginning in October 2018. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (presently Decipher Biosciences), PLUS Diagnostics (presently Inform Diagnostics) and Genoptix.  She holds an MA in education from Stanford University, and an MS in biology and BS in Biochemistry and Cell Biology from the University of California, San Diego.

Feb 12, 2020

PreludeDx: Edwin Hendrick

PreludeDx has appointed Edwin Hendrick as the company's chief commercial officer. He has more than 30 years of related commercial experience and was most recently at Biocept. Before that, he was at Decipher Biosciences, formerly called GenomeDx, and at Plus Diagnostics. Laguna Hills, California-based PreludeDx's main product is the DCISionRT risk assessment test for patients with ductal carcinoma in situ

Feb 10, 2020

GenMark Diagnostics: Scott Mendel, Hany Massarany, Kevin O’Boyle, James Fox

GenMark Diagnostics has appointed Scott Mendel, its chief operating officer, as interim president and CEO, effective immediately. Hany Massarany has stepped down as president and CEO and as a member of the company’s board of directors, also effective immediately. GenMark said it has commenced a search to identify a permanent CEO.

The firm appointed Kevin O’Boyle as chairman of the board. James Fox, GenMark’s prior chairman, will remain on the board as a non-executive director.

Feb 05, 2020

Luna Genetics: Arthur Beaudet

Arthur Beaudet has retired from Baylor College of Medicine, where he was a professor of molecular and human genetics, molecular and cellular biology, and pediatrics. He is now full-time CEO of Luna Genetics, a startup he cofounded in 2018 that aims to develop fetal cell-based noninvasive prenatal tests.

Feb 05, 2020

Aperiomics: Elizabeth Pyle

Aperiomics has appointed Elizabeth Pyle as chief operating officer. Prior to joining Aperiomics, she directed the University of Virginia's National Sciences Entrepreneurship Program and founded consulting firm Pyle & Associates. Aperiomics leverages metagenomic sequencing and big data to identify every known bacteria, virus, fungus, and parasite. 

Feb 05, 2020

NeoGenomics: Kathryn McKenzie, William Bonello, Douglas Brown

NeoGenomics announced three leadership appointments: Kathryn McKenzie as CFO, William Bonello as president of the informatics division, and Douglas Brown as chief strategy and corporate development officer. McKenzie was previously the VP of finance and chief accounting officer after joining NeoGenomics in 2017. She was also the assistant controller and director of financial reporting and treasury at Chico's FAS, and worked at Ernst and Young. 

Bonello was previously the chief strategy and corporate development officer at NeoGenomics and will continue as director of investor relations, which he's been since 2018. Before joining NeoGenomics, he was a healthcare equity analyst at Craig-Hallum and senior VP for investor relations at Laboratory Corporation of America. 

Brown is joining NeoGenomics from SVB Leerink, where he was senior managing director. He recently advised NeoGenomics on the acquisition of GenOptix and the oncology assets of Human Longevity. 

Jan 29, 2020

Unilabs: Alessandre Keller

Unilabs has appointed Alessandre Keller the general manager of Unilabs Switzerland, effective immediately. Martin Schlatter, who had been the Swiss GM, will support Keller to ensure continuity, the company said. Schlatter remains Unilabs' group regional director centre and chief commercial officer. Keller was previously the global business head for Maternal, Infant & Toddler Health & Nutrition solutions at Nestlé. 

Jan 28, 2020

Interpace Biosciences: Fortunato Ron Rocca, Felice Schnoll-Sussman, James Early, Fred Knechtel, Jeff Salzman

Interpace Biosciences has appointed Fortunato Ron Rocca as a class II director. Rocca will serve on the firm's board as a non-employee director. Concurrently with the appointment, Felice Schnoll-Sussman has resigned from Interpace Bio's board. Rocca currently serves as president and CEO of Exagen.

Interpace Bio also said that CFO and Treasurer James Early is retiring from the firm. Early will be replaced by Fred Knechtel, who previously served as CFO at Genewiz. 

Interpace Bio has also appointed Jeff Salzman as VP of managed care and payor relations. Prior to Interpace Bio, Salzman held roles at Quest Diagnostics, Monogram Biosciences, Vermillion, and most recently at CareDx. 

Jan 27, 2020

BioSoft Integrators: Debbie Bowers

BioSoft Integrators, a provider of informatics solutions for life science research and clinical diagnostic laboratories, has appointed Debbie Bowers as president and chief commercial officer. Bowers joined BioSoft as vice president of commercial operations in November 2017. Prior to joining BioSoft, she was VP of robotic operations at Hamilton Robotics. Prior to that, she was a VP of business development at Invetech, a then Danaher company that provides development and contract manufacturing services to global research, clinical, and consumer companies.

Jan 27, 2020

Biocartis: Ewoud Welten

Biocartis announced that CFO Ewoud Welten has decided to resign from the firm to pursue an opportunity in the Netherlands. Having served at Biocartis for about five years, Welten will stay with the firm until April. Biocartis has begun a selection process to recruit a new CFO

Jan 27, 2020

QuantuMDx: Jonathan O'Halloran, Neil Butler, Elaine Warburton, John Burn

QuantuMDx announced the appointments of Jonathan O'Halloran as CEO and Neil Butler as chairman of the board as the company begins its transition to commercialization.

A cofounder and former CSO of the firm, O'Halloran invented many of its proprietary technologies. He has a background in genetics and genomics and has been focusing on tuberculosis and antimicrobial resistance for the past 12 years.

QuantuMDx appointed Neil Butler to its board as a non-executive director in July 2019. He also serves on the boards of Nidor Dx, Radisens, and Spectromics and previously served as chair and non-executive director for Binx Health and Genomic Vision.

QuantuMDx said its CEO and Cofounder Elaine Warburton will move into the role of non-executive director and continue to support QuantuMDx in an ambassadorial role, including with key strategic projects. John Burn will step back as chairman, a role he had undertaken upon the company's inception in 2008, and become vice-chairman of the board of directors.